Thursday, August 16, 2012

Aspen and GSK strike another deal

Aspen management has announced it will purchase a 25-strong portfolio of products in Australia from GSK for 2.1x sales. The deal relates to a portfolio of 25 off-patent products including Lamictal (epilepsy), Zofran (anti-emetic), Augmentin (antibiotic) and Valtrex (herpes). The portfolio generated 2011 sales of £83m,

No comments:

Post a Comment